You can whack it with a hammer, attack it with a drill, even stab it with a screwdriver. But try as you might, you won’t be able to tamper with a high-tech pill dispenser designed by mechanical engineering students at Johns Hopkins University’s Whiting School of Engineering.

Which is exactly the point.

The U.S. Centers for Disease Control and Prevention has estimated that drug overdoses kill more than 44,000 Americans annually, including more than 16,000 deaths from prescription drugs. Federal officials also say that at least one in 20 Americans ingests drugs prescribed for someone else. Concerned about these alarming statistics, experts at the Johns Hopkins Bloomberg School of Public Health’s Center for Injury Research and Policy challenged a team of Johns Hopkins senior mechanical engineers to design and build an anti-theft and tamper-resistant pill dispenser.

‘We needed this personal pill ‘safe’ to have tamper resistance, personal identification capabilities, and a locking mechanism that allows only a pharmacist to load the device with pills,’ said Kavi Bhalla, assistant professor at the university’s Bloomberg School of Public Health and one of the team’s mentors for the project.

Classmates Megan Carney, Joseph Hajj, Joseph Heaney, and Welles Sakmar

Using apheresis to remove a serum protein called soluble Fms-like tyrosine kinase-1 (Sflt-1) may help pregnant women with severe preeclampsia safely delay delivery, according to a pilot study.

‘Based on recent advances in the understanding of this condition, we and others are developing treatments for preeclampsia to allow women to safely prolong their pregnancy if they are suffering from very preterm preeclampsia,’ first author Ravi Thadhani, MD, MPH, from Massachusetts General Hospital in Boston, said in a press release.

Symptoms of preeclampsia include high blood pressure and proteinuria. The condition affects between 3% and 8% of pregnancies worldwide and can be harmful or even fatal to both the mother and newborn. Because of limited understanding about its underlying mechanisms, no cure exists other than delivery, which can be problematic if preeclampsia develops very early in pregnancy, the authors note.

In the open pilot study, Dr Thadhani and colleagues tested the safety and efficacy of removing sFlt-1 from the blood of pregnant women with very preterm preeclampsia. The serum protein sFLT-1 acts as a receptor for vascular endothelial growth factor. By inhibiting vascular endothelial growth factor activity, sFTL-1 modifies blood vessel growth. Women with preeclampsia often have elevated sFTL-1 levels.

Using apheresis, researchers removed the blood from 11 pregnant women and passed it through a negatively charged dextran sulfate column to bind and remove the positively charged sFLT-1. Participants were aged 20 to 38 years and were between 23 to 32 weeks of gestation. Inclusion criteria included systolic blood pressure of 140 mm Hg or higher or diastolic blood pressure of 90 mm Hg or higher, new-onset protein/creatinine ratio higher than 0.30 g/g, and sFLT-1/placental growth factor ratio higher than 85.

Apheresis resulted in an 18% (range, 7% – 28%) reduction in mean sFLT-1 levels, as well as reductions of 44% in protein/creatinine ratios.

Pregnancy continued 8 days after admission (range, 2 – 11 days) in six women treated once with apheresis, and 12 days (range, 7 – 19 days) in five women treated multiple times. In comparison, delivery occurred after 3 days (range, 0 – 14 days) in untreated women with preeclampsia (n = 22) and women who delivered preterm for other reasons (n = 22); the control participants, who had been treated contemporaneously, were matched to the treated women for several factors, including gestational age at delivery.

Although antihypertensive treatments were withheld the morning of the apheresis treatment, the most common adverse effect of apheresis was transient hypotension, which was treated with saline hydration and decreasing blood flow through the column. Hypotension was not severe enough to cause any of the women to stop treatments. No significant changes in foetal heart monitoring occurred during apheresis.

Babies born to apheresis-treated women needed fewer days of supplemental oxygen than babies born to untreated women. However, neonatal test results, total days in the neonatal ICU, and days spent in the hospital did not differ between the groups.

‘Our pilot study suggested we can safely prolong pregnancy when we target removal of sFlt-1 in women with severe preterm preeclampsia, and we hope this is confirmed in randomized trials,’ Dr Thadhani. MedScape

Thrombosis is a common side-effect occurring with graft or stent placement because of inevitable damage of the blood vessel wall and it leads to partial or complete blockage of the vessel. To eliminate this consequence the new thrombolytic sol

Researchers from North Carolina State University, Institut Langevin and Paris-Descartes University have conducted a proof-of-concept study that raises the possibility of using ultrasound techniques to detect cervical stiffness changes that indicate an increased risk of preterm labour in pregnant women. While additional work needs to be done, it may ultimately give doctors a new tool for determining when to provide treatment that can prevent preterm birth.
Premature births can mean low birth-weights and other medical problems for newborns, but there are steps that doctors can take to reduce the chances of premature birth if early warning signs are detected. One of those early symptoms is a softening of the cervix. Traditionally, this stiffness is assessed by manually palpating the cervix.

Penn Medicine has performed more than 1,200 Transcatheter Aortic Valve Replacements (TAVR) on patients with severe aortic stenosis. At the Transcatheter Cardiac Therapeutics conference in San Francisco, Howard C. Herrmann, MD, the John Winthrop Bryfogle Professor of Cardiovascular Diseasesand director of Penn Medicine